Mercer Global Advisors
MPLT

Mercer Global Advisors’s MapLight Therapeutics MPLT Stock Holding History

Mercer Global Advisors’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1K Buy
+590
New +$17K ﹤0.01% 4792

Other funds holding MPLT

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Mercer Global Advisors's MPLT Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in MapLight Therapeutics (MPLT) in Q2 2026: 590 shares worth $21.1K. The stake represents ﹤0.01% of the portfolio and ranks #4792 among its holdings.

80 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Mercer Global Advisors held 590 shares of MapLight Therapeutics worth $21.1K as of Q2 2026.
  • MapLight Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • MapLight Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4792 holding.
  • 80 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.